Description:
Technology Summary
Alcohol use disorder (AUD) affects millions of people worldwide and lacks a strong pharmaceutical option for treatment. Minocycines have been shown to have great therapeutic potential due to their positive interactions with the central nervous system, their main drawback being unwanted bactericidal effects. This technology encompasses a number of modified minocycline compounds and their method of use. These compounds shed their problematic antibiotic effects, yet retain potency against AUD, pain, and other inflammatory conditions.
Reference Number
D-1521
D-1429
Market Applications
-Therapeutics
-Medical Research
Features, Benefits & Advantages
-treats alcohol use disorder
-therapeutic use against inflammatory processes and pain
-compounds have had bactericidal effects removed
Intellectual Property
Two provisional patents were filed on 6/13/18 with serial numbers 62684509 and 62684467.
Development Stage
Initial testing has been done in mice and in-vitro models.
Researchers
Dr. Ted Reid, Associate Professor Department of Microbiology and Immunology, Vice Chairman Department of Opthamology, Texas Tech University Health Sciences Center
Dr. Susan Bergeson, Associate Professor, Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center
Keywords
minocycline, tetracycline, derivative, modified, compound, alcoholism, AUD, SUD, antibiotic, treatment, innate immune, inflammation, pain, therapeutic